Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...

Currently, their treatment options are ... like atopic dermatitis and eosinophilic asthma. The other is chronic spontaneous urticaria (CSU), for which Dupixent was turned down in 2023 but refiled ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

You should not receive a “live vaccine” right before and during treatment with DUPIXENT. are pregnant ... or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or ...

Five times more adults on Dupixent achieved sustained disease ... Moreover, current treatment options can be challenging for this primarily elderly patient population because they work by ...

“Data on the efficacy and durability of biologic treatments ... with asthma who received an approved biologic therapy — omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Sanofi ...

n=3), asthma (n=4 vs. n=1), conjunctivitis ... You should not receive a “live vaccine” right before and during treatment with DUPIXENT. are pregnant or plan to become pregnant.

Five times more adults on Dupixent achieved sustained disease ... added to standard-of-care oral corticosteroids (OCS). During treatment, all patients underwent a protocol-defined OCS tapering ...

n=3), asthma (n=4 vs. n=1), conjunctivitis (n=4 vs ... You should not receive a “live vaccine” right before and during treatment with DUPIXENT. are pregnant or plan to become pregnant. It is not known ...